Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 1508242 | HLA MATCHED (HLA-MATCHED) | cadaver | NA | NA | NA | unclassified | |
| a total of 1386 cadaveric kidneys were shipped from 108 organ centers to 198 transplantation centers and distributed among hla-matched recipients, 1004 of whom were receiving a first transplant and 382 of whom were receiving a subsequent transplant. | |||||||
| 1508242 | HLA MATCHED (HLA-MATCHED) | cadaver | NA | NA | NA | unclassified | |
| survival of nationally shared, hla-matched kidney transplants from cadaveric donors. | |||||||
| 1508243 | HLA (HLA) | transplantation | NA | NA | NA | positive | |
| according to univariate analysis, only the recipient's age at transplantation, the number of mismatches for hla antigens, the type of insurance coverage, the source of referral for transplantation, and the degree of compliance correlated significantly with the rate of graft survival. | |||||||
| 1508243 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| according to proportional-hazards analysis, the only factors contributing to a lower rate of graft survival were age of less than 30 years at transplantation (relative risk, 2.3; 95 percent confidence interval, 1.3 to 4.6), mismatches for all six hla antigens as compared with three or fewer mismatches (relative risk, 5.6; 95 percent confidence interval, 3.3 to 9.6), and coverage by medicaid or medicare (relative risk, 2.2; 95 percent confidence interval, 1.5 to 3.2). | |||||||
| 1508243 | HLA (HLA) | cadaver | NA | NA | NA | unclassified | |
| when immunosuppression is equivalent in black and white transplant recipients, apparently race-related differences in the long-term survival of renal cadaveric allografts appear to be related to other factors that affect graft survival unfavorably, notably poor hla matching and unfavorable socioeconomic factors. | |||||||
| 1508243 | HLA-A (HLA-A) | end-stage renal disease | NA | NA | NA | only_studied | |
| we evaluated differences in the cause and duration of end-stage renal disease, the number of pretransplantation transfusions, age, matching for hla-a, b, and dr antigens, race of the donor, insurance coverage, and compliance to assess their effect on graft survival in both groups. | |||||||
| 1508243 | HLA-DR (HLA-DR) | end-stage renal disease | NA | NA | NA | only_studied | |
| we evaluated differences in the cause and duration of end-stage renal disease, the number of pretransplantation transfusions, age, matching for hla-a, b, and dr antigens, race of the donor, insurance coverage, and compliance to assess their effect on graft survival in both groups. | |||||||
| 1514963 | HLA-A (HLA-A) | transplantation | NA | NA | NA | unclassified | |
| a total of seven covariates appeared to influence graft survival significantly: the period of transplantation (p = 10(-8)), retransplantations (p = 0.003), age and sex of the donor (p = 0.003 and 0.009 respectively), duration of pretransplant dialysis (p = 0.03), pretransplant sensitization to hla antigens (p = 0.05), and matching for hla-a, -b, and -dr loci (p = 0.03). | |||||||
| 1514963 | HLA-DR (HLA-DR) | transplantation | NA | NA | NA | unclassified | |
| a total of seven covariates appeared to influence graft survival significantly: the period of transplantation (p = 10(-8)), retransplantations (p = 0.003), age and sex of the donor (p = 0.003 and 0.009 respectively), duration of pretransplant dialysis (p = 0.03), pretransplant sensitization to hla antigens (p = 0.05), and matching for hla-a, -b, and -dr loci (p = 0.03). | |||||||
| 1515884 | HLA IDENTICAL (HLA-IDENTICAL) | etoposide | NA | cyclophosphamide | NA | unclassified | |
| NA | |||||||
Copyright 2024